These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 18387935)

  • 1. The hope and fear of rimonabant.
    Rumsfeld JS; Nallamothu BK
    JAMA; 2008 Apr; 299(13):1601-2. PubMed ID: 18387935
    [No Abstract]   [Full Text] [Related]  

  • 2. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.
    Nissen SE; Nicholls SJ; Wolski K; Rodés-Cabau J; Cannon CP; Deanfield JE; Després JP; Kastelein JJ; Steinhubl SR; Kapadia S; Yasin M; Ruzyllo W; Gaudin C; Job B; Hu B; Bhatt DL; Lincoff AM; Tuzcu EM;
    JAMA; 2008 Apr; 299(13):1547-60. PubMed ID: 18387931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome treatment strategies.
    Fujioka K
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rimonabant actions on cardiometabolic risk factors].
    Stiefelhagen P
    Med Monatsschr Pharm; 2007 Jan; 30(1):39-40. PubMed ID: 17260652
    [No Abstract]   [Full Text] [Related]  

  • 6. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?
    Pacher P
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):7-9. PubMed ID: 19092136
    [No Abstract]   [Full Text] [Related]  

  • 7. Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.
    Prescrire Int; 2007 Dec; 16(92):250. PubMed ID: 18092422
    [No Abstract]   [Full Text] [Related]  

  • 8. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
    Ward SJ; Raffa RB
    Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
    [No Abstract]   [Full Text] [Related]  

  • 9. [Sleep disorders associated with treatment with rimonabant].
    Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
    Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
    [No Abstract]   [Full Text] [Related]  

  • 10. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen AJ
    J Neuroendocrinol; 2008 May; 20 Suppl 1():139-46. PubMed ID: 18426513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 13. Rimonabant, obesity and diabetes.
    Prescrire Int; 2007 Jun; 16(89):122. PubMed ID: 17585427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.
    Hollander P
    Am J Med; 2007 Feb; 120(2 Suppl 1):S18-28; discussion S29-32. PubMed ID: 17296341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].
    Roussel R
    Ann Endocrinol (Paris); 2007 Jun; 68 Suppl 1():33-5. PubMed ID: 17961659
    [No Abstract]   [Full Text] [Related]  

  • 16. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.
    Dol-Gleizes F; Paumelle R; Visentin V; Marés AM; Desitter P; Hennuyer N; Gilde A; Staels B; Schaeffer P; Bono F
    Arterioscler Thromb Vasc Biol; 2009 Jan; 29(1):12-8. PubMed ID: 18845788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trial comes too late as psychiatric side effects end hope for rimonabant.
    Stapleton JA
    Addiction; 2009 Feb; 104(2):277-8. PubMed ID: 19149824
    [No Abstract]   [Full Text] [Related]  

  • 20. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.